Major Advances in Gynecologic Oncology in 2025: Systematic Review and Synthesis of Conference and Published Evidence - PubMed
5 hours ago
- #immunotherapy
- #gynecologic oncology
- #clinical trials
- Major advances in gynecologic oncology in 2025, focusing on cervical, ovarian, endometrial, and vulvar cancers.
- Systematic review following PRISMA 2020 guidelines, analyzing 23 studies (17 phase-III RCTs and 6 non-phase III RCTs/early-phase studies).
- Key findings include pembrolizumab combined with chemoradiotherapy as a new standard for high-risk locally advanced cervical cancer (KEYNOTE-A18 trial).
- Sentinel lymph node biopsy validated as a safe surgical de-escalation strategy in cervical cancer (PHENIX trial).
- First statistically significant overall survival improvement with an immune checkpoint inhibitor in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96 trial).
- Novel therapeutic mechanisms like glucocorticoid receptor modulation (ROSELLA trial) and cadherin-6-targeted antibody-drug conjugates (REJOICE-Ovarian01) showed efficacy in ovarian cancer.
- First-line immuno-chemotherapy solidified in endometrial cancer with differential benefits based on mismatch repair status (NRG GY018 and RUBY trials).
- Anti-PD-1 therapy demonstrated meaningful clinical activity in advanced vulvar cancer.
- Circulating tumor DNA analysis from the CALLA trial provided insights into biomarker dynamics in cervical cancer.
- New standards of care emphasize biomarker-driven approaches, immunotherapy integration, and novel mechanisms to overcome resistance.